Ripretinib for the treatment of advanced, imatinib‐resistant gastrointestinal stromal tumors
出版年份 2023 全文链接
标题
Ripretinib for the treatment of advanced, imatinib‐resistant gastrointestinal stromal tumors
作者
关键词
-
出版物
Journal of Digestive Diseases
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-09-14
DOI
10.1111/1751-2980.13229
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, open-label study in China.
- (2023) Jian Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
- (2023) Hans Gelderblom et al. EUROPEAN JOURNAL OF CANCER
- KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment
- (2022) Andrea Napolitano et al. CHEMOTHERAPY
- INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
- (2022) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
- (2022) Jordan Senchak et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
- (2022) Jian Li et al. CLINICAL CANCER RESEARCH
- Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval
- (2022) Caitriona Goggin et al. Future Oncology
- Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
- (2022) Sebastian Bauer et al. JOURNAL OF CLINICAL ONCOLOGY
- 1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study
- (2021) M. von Mehren et al. ANNALS OF ONCOLOGY
- Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogenous KIT/PDGFRA mutations in the phase 3 INVICTUS study
- (2021) Sebastian Bauer et al. CLINICAL CANCER RESEARCH
- Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
- (2021) Suzanne George et al. EUROPEAN JOURNAL OF CANCER
- Molecular Pathogenesis of Gastrointestinal Stromal Tumor: A Paradigm for Personalized Medicine
- (2021) Josephine K. Dermawan et al. Annual Review of Pathology-Mechanisms of Disease
- Gastrointestinal stromal tumor: challenges and opportunities for a new decade
- (2020) César Serrano et al. CLINICAL CANCER RESEARCH
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2020) Jean-Yves Blay et al. LANCET ONCOLOGY
- Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
- (2020) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
- (2019) Bryan D. Smith et al. CANCER CELL
- Gastrointestinal Stromal Tumors
- (2018) Margaret von Mehren et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
- (2018) Sergei Boichuk et al. MOLECULES
- Gastrointestinal Stromal Tumors, Version 2.2014
- (2017) Margaret von Mehren et al. Journal of the National Comprehensive Cancer Network
- Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
- (2016) Kjetil Søreide et al. Cancer Epidemiology
- Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance
- (2014) N. Javidi-Sharifi et al. CANCER RESEARCH
- Gastrointestinal stromal tumour
- (2013) Heikki Joensuu et al. LANCET
- Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors
- (2012) Jian Li et al. Future Oncology
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
- (2009) K. S. Gajiwala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
- (2008) Toshirou Nishida et al. CANCER SCIENCE
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started